
LGD-4033 Ligandrol
LGD-4033 (Ligandrol) binds androgen receptors in muscle and bone, driving protein synthesis and lean tissue accretion through downstream anabolic signaling. Phase I clinical data demonstrates dose-dependent lean mass gains in healthy volunteers; users commonly employ it during mass phases or caloric deficits for tissue preservation. Offered now as EXO-COATED pellets — proprietary external coating engineered for maximum bioavailability. Currently backordered; capsules and liquid formats are launching soon. Research compound — preorder interest only.
Currently offered as EXO-COATED pellets for maximum bioavailability. Reserve a quantity (30 / 60 / 90 / 180) or ask to be notified at next batch.
Capsules and liquid formats are launching soon — submit interest below for early-access notification.
Related products

GW-501516 Cardarine

MK-2866 Ostarine

MK-677 Ibutamoren
